Skip to main content
. 2018 Feb 24;7(5):e006463. doi: 10.1161/JAHA.117.006463

Table 2.

Replication of the Linkage‐Disequilibrium Pruned SNPs With P Value <0.00001 From the GWAS Meta‐Analysis of β‐Blockers HR Response in PEAR‐2 Participants Treated With Metoprolol

Race SNP A1 FRQ Rsqa Meta Effect Meta SE Meta P Value Dir PEAR‐2 Effect PEAR‐2 SE PEAR‐2 P Value Rsqb
Blackc rs17117817c Tc 0.93c 1.00 to 0.82c −5.73c 1.11c 2E‐07c −−c −5.05c 1.65c 2.2E‐03c 1.00c
Black rs10809249 T 0.82 0.95 to 0.99 −3.52 0.74 2E‐06 −− −0.57 0.98 0.56 0.99
Black rs12890215 T 0.82 1.01 to 1.03 −3.4 0.72 2E‐06 −− −0.48 0.92 0.602 1.00
Black rs1045580 T 0.85 0.95 to 1.02 3.56 0.76 2E‐06 ++ 0.62 1.02 0.53 1.00
Black rs2806495 A 0.10 0.96 to 0.82 4.67 0.99 2E‐06 ++ −0.53 1.29 0.67 1.00
Black rs7738600 A 0.51 1.05 to 1.03 −2.6 0.56 4E‐06 −− −0.24 0.71 0.73 1.00
Black rs11757000 T 0.77 0.99 to 0.91 −3.05 0.67 5E‐06 −− 0.35 0.91 0.69 1.00
Black rs7042878 C 0.09 1.05 to 1.10 4.31 0.95 5E‐06 ++ 1.65 1.35 0.22 1.00
Blackc rs2364349c Ac 0.18c 0.87 to 0.92c 3.43c 0.76c 7E‐06c ++c 3.64c 1.03c 4E‐04c 0.98c
Black rs4733278 T 0.46 0.82 to 0.99 −2.62 0.58 7E‐06 −− 0.01 0.75 0.98 0.99
Black rs11069252 T 0.92 0.92 to 1.00 −4.76 1.06 7E‐06 −− 1.21 1.37 0.37 1.00
Black rs12417208 A 0.84 0.89 to 0.82 −3.76 0.84 8E‐06 −− −1.43 1.09 0.19 0.93
Black rs3759422 T 0.46 0.91 to 1.06 2.5 0.56 8E‐06 ++ 0.77 0.69 0.26 1.00
Black rs1018353 T 0.9 0.95 to 0.85 −4.29 0.96 8E‐06 −− 0.94 1.37 0.49 1.00
Black rs4554901 T 0.07 0.93 to 1.03 4.85 1.09 8E‐06 ++ −0.09 1.41 0.94 0.99
Black rs10145648 T 0.74 0.98 to 1.00 −2.85 0.64 8E‐06 −− −0.34 0.77 0.65 1.00
Black rs10809367 A 0.14 1.18 to 1.18 3.41 0.77 9E‐06 ++ 0.95 1.18 0.42 1.00
Black rs10499 A 0.95 0.94 to 1.10 −5.67 1.28 9E‐06 −− −2.01 2.00 0.31 1.00
Blackc rs6455914c Tc 0.22c 0.97 to 0.93c 3.08c 0.7c 1E‐05c ++c 1.73c 0.83c 0.03c 0.99c
Black rs6470259 A 0.80 0.94 to 0.88 −3.2 0.72 1E‐05 −− −0.76 1.01 0.44 0.94
White rs955395 A 0.36 0.99 to 0.96 −1.7 0.35 9E‐07 −− 0.21 0.59 0.69 0.99
White rs11727192 T 0.21 0.94 to 0.97 −1.92 0.42 5E‐06 −− −0.80 0.77 0.29 1.00
White rs10516175 A 0.12 1.09 to 1.02 2.17 0.48 6E‐06 ++ 0.46 0.79 0.64 0.99
White rs13160161 A 0.37 1.07 to 0.97 −1.5 0.33 7E‐06 −− −0.34 0.67 0.71 1.00
White rs11641210 T 0.89 0.99 to 1.00 2.32 0.52 8E‐06 ++ −0.50 1.00 0.61 0.99

A1 indicates coded allele; Dir, the direction of effect; FRQ, coded allele frequency; GWAS, genome‐wide association study; HR, heart rate; PEAR, Pharmacogenomic Evaluation of Antihypertensive Responses; POS, position; SNP, single nucleotide polymorphism.

a

Rsq, r‐squared imputation quality metric in the discovery analysis in which the first number represents the imputation quality for the presented SNP in PEAR monotherapy and the second number represents the imputation quality for the presented SNP in PEAR add‐on therapy.

b

Rsq, r‐squared imputation quality metric in the replication analysis (PEAR2).

c

Represent polymorphisms with a P value <0.05 in the replication cohort and the effect of the polymorphism on HR in response to β‐blockers is in the same direction in the discovery (Meta Effect) and replication (PEAR‐2 Effect) analysis. Meta represents meta‐analysis between PEAR β‐blocker mono‐ and add‐on therapy.